The m$^6$A demethylase ALKBH5-mediated upregulation of DDIT4-AS1 maintains pancreatic cancer stemness and suppresses chemosensitivity by activating the mTOR pathway

Yi Zhang$^{1,2*}$, Xiaomeng Liu$^1$, Yan Wang$^1$, Shihui Lai$^{1,3}$, Zhiqian Wang$^{1,3}$, Yudie Yang$^1$, Wenhui Liu$^1$, Hongquan Wang$^1$ and Bo Tang$^1$

Abstract

Background: Chemoresistance is a major factor contributing to the poor prognosis of patients with pancreatic cancer, and cancer stemness is one of the most crucial factors associated with chemoresistance and a very promising direction for cancer treatment. However, the exact molecular mechanisms of cancer stemness have not been completely elucidated.

Methods: m$^6$A-RNA immunoprecipitation and sequencing were used to screen m$^6$A-related mRNAs and lncRNAs. qRT-PCR and FISH were utilized to analyse DDIT4-AS1 expression. Spheroid formation, colony formation, Western blot and flow cytometry assays were performed to analyse the cancer stemness and chemosensitivity of PDAC cells. Xenograft experiments were conducted to analyse the tumour formation ratio and growth in vivo. RNA sequencing, Western blot and bioinformatics analyses were used to identify the downstream pathway of DDIT4-AS1. IP, RIP and RNA pulldown assays were performed to test the interaction between DDIT4-AS1, DDIT4 and UPF1. Patient-derived xenograft (PDX) mouse models were generated to evaluate chemosensitivities to GEM.

Results: DDIT4-AS1 was identified as one of the downstream targets of ALKBH5, and recruitment of HuR onto m$^6$A-modified sites is essential for DDIT4-AS1 stabilization. DDIT4-AS1 was upregulated in PDAC and positively correlated with a poor prognosis. DDIT4-AS1 silencing inhibited stemness and enhanced chemosensitivity to GEM (Gemcitabine). Mechanistically, DDIT4-AS1 promoted the phosphorylation of UPF1 by preventing the binding of SMG5 and PP2A to UPF1, which decreased the stability of the DDIT4 mRNA and activated the mTOR pathway. Furthermore, suppression of DDIT4-AS1 in a PDX-derived model enhanced the antitumour effects of GEM on PDAC.
Background

Pancreatic cancer is a prevalent gastrointestinal malignancy worldwide and is characterized by a late diagnosis, poor prognosis and high mortality. Pancreatic cancer is currently the 4th leading cause of cancer-related death, with a 5-year survival rate of only approximately 10% [1]. Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. Gemcitabine (GEM) is the first-line chemotherapeutic agent for pancreatic cancer, and adjuvant chemotherapy with GEM has been shown to significantly prolong the overall survival and disease-free survival of patients with pancreatic cancer [2]. However, the resistance of malignant tumour cells to GEM remarkably affects the efficacy of treatment. Cancer stem cells (CSCs) are an important factor contributing to chemotherapy resistance in pancreatic cancer [3]. CSCs have self-renewal and multilineage differentiation abilities, which are associated with drug resistance, recurrence, and metastasis of malignant tumours [4]. Nevertheless, the mechanisms by which CSCs affect the progression and drug resistance of pancreatic cancer remain obscure and require further exploration.

N6-methyladenosine (m6A) mRNA modification is a highly prevalent in RNA and plays an important role in cancer initiation and progression [5, 6]. The m6A modification mediates mRNA stability and translation efficiency [7]. This modification is installed by the writers METTL3 and METTL14 and can be removed by the erasers FTO and ALKBH5 [8]. ALKBH5 belongs to the AlkB family of nonheme Fe(II)/a-ketoglutarate-dependent dioxygenases. ALKBH5 was reported to mediate the hypoxia-induced and hypoxia-inducible factor (HIF)-dependent breast CSC phenotype [9]. Furthermore, our previous studies reported the downregulation of ALKBH5 in a GEM-treated patient-derived xenograft (PDX) model, and its overexpression sensitizes PDAC cells to chemotherapy [10], suggesting its potential roles in regulating stemness and chemosensitivity. However, the regulatory mechanisms of ALKBH5 remain largely unknown.

DNA damage-inducible transcript 4 (DDIT4), also called DNA damage response 1 (REDD1) and stress-triggered protein (RTP801), consists of 232 amino acids and is mainly found in the cytoplasm and nucleus [11, 12]. Upon stress induction, including oxidative stress, endoplasmic reticulum stress, hypoxia and starvation [11, 13–15], DDIT4 inhibits mTOR signalling by stabilizing the tuberous sclerosis complex (TSC1-TSC2) [16, 17], DDIT4 is aberrantly expressed at low levels in multiple tumours, including gastric cancer [18], breast cancer [19], glioma [20] and other tumours [21–23]. The antisense transcript of DDIT4 encodes the IncRNA DDIT4-AS1, which has a length of 847 bp and consists of two exons. Numerous studies have indicated that abnormal expression of antisense IncRNAs contributes to tumorigenesis, oncogenic progression and the hallmarks of cancer [24]. However, the function of DDIT4-AS1 has not been previously reported.

In this study, we identified DDIT4-AS1 as a downstream target of ALKBH5, and recruitment of HuR onto m6A-modified sites is essential for DDIT4-AS1 stabilization. We also described the function of DDIT4-AS1 in maintaining pancreatic cancer stemness and suppressing chemosensitivity. Mechanistically, DDIT4-AS1 recruits UPF1 to destabilize DDIT4 and activate the mTOR pathway, suggesting the crucial roles of DDIT4-AS1 in cancer progression.

Conclusions: The ALKBH5-mediated m6A modification led to DDIT4-AS1 overexpression in PDAC, and DDIT-AS1 increased cancer stemness and suppressed chemosensitivity to GEM by destabilizing DDIT4 and activating the mTOR pathway. Approaches targeting DDIT4-AS1 and its pathway may be an effective strategy for the treatment of chemotherapy resistance in PDAC.

Keywords: ALKBH5, Stemness, Chemosensitivity, DDIT4-AS1, UPF1

Materials and methods

Patient samples

This study included 40 pairs of fresh PDAC tissues obtained from the First Affiliated Hospital of Guangxi Medical University (GXMU) that were stored at −80 °C immediately after surgery. We obtained informed consent from all patients. The study was approved by the Ethics Committee of the Provincial Clinical College of GXMU based on the ethical guidelines of the 1975 Declaration of Helsinki. The clinicopathological characteristics included age, sex, tumour nodule number, aetiology, tumour stage, tumour size, tumour differentiation, and vascular invasion. The tumour classification and grade were determined based on the TNM classification.

Chemicals and antibodies

Lipofectamine 2000 transfection reagents and total RNA extraction agent (TRIzol) were purchased from Invitrogen (Grand Island, NY, USA). Antibodies against Ki67, DDIT4, ALKBH5, Mettle3, HuR, Caspase-3, mTOR, p-mTOR, p-ULK, p-Ps70S6K, CD133, and CD44 were obtained from Abcam (Cambridge, MA, USA), whereas those against OCT4, SOX2, and EpCAM were obtained
from Cell Signaling Technology (Danvers, MA, USA). UPF1 antibodies were purchased from Becton Dickinson. Unless indicated otherwise, all other chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA). Details of antibody information are provided in Supplementary materials.

Cell lines and cell culture
The human cell lines 293 T, AsPC-1, PANC-1, BxPC-3, HPDE6-C7, CFPAC-1, and SW1990 were purchased from American Type Culture Collection (ATCC). Cells were cultured in DMEM (Gibco, Grand Island, New York, USA) supplemented with 10% foetal bovine serum (FBS, Gibco), 1% penicillin and 1% streptomycin and incubated in an incubator with 5% CO2 at 37 °C.

Quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA was extracted using TRizol reagent (Invitrogen), and complementary DNA (cDNA) templates were synthesized using SuperScript II Reverse Transcriptase (Invitrogen). Quantitative reverse transcription-PCR (qRT-PCR) and data collection were performed with an ABI PRISM 7900HT sequence detection system.

Total RNA was extracted from selected cells or tissues using TRizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. Complementary DNA (cDNA) templates were synthesized using SuperScript II Reverse Transcriptase (Invitrogen). Fast Start Universal SYBR Green Master Mix (Roche Diagnostics GmbH, Mannheim, Germany) was used for qRT-PCR. The primers used to detect mRNA levels are listed in Supplementary materials.

Immunohistochemistry (IHC)
IHC was performed on paraformaldehyde-fixed, paraffin-embedded tissue specimens following heat-mediated antigen retrieval in citrate buffer (0.01 M, pH 6.0). Endogenous peroxidase activity was blocked with 3% H2O2 for 15 min at room temperature (RT). Thereafter, the sections were incubated with goat serum for 1 h to block the nonspecific binding sites and then with primary antibodies overnight at 4 °C. After three rinses with PBS for 5 min each, the sections were further incubated with horseradish peroxidase-conjugated secondary antibodies for 1 h at RT. Each section was then rinsed with PBS three times for 5 min each, and the reactions were developed using diaminobenzidine tetrahydrochloride (DAB) as a substrate. Cellular nuclei were counterstained using haematoxylin, and the sections were sealed with neutral gum. Images were obtained using an Olympus X71 inverted microscope (Olympus Corp., Tokyo, Japan).

Plate colony-forming and sphere-forming assays
For the plate colony-forming assay, PC cells were plated into 6-well plates at a density of 5 × 10^2 cells per well and cultured for 14 days. After the incubation, the cells were rinsed with PBS, fixed with methanol/acetic acid (3:1, v/v), and then stained with 0.5% crystal violet (Sigma-Aldrich, St. Louis, MO, USA). Mammosphere culture was performed as described by Dontu et al. Single-cell suspensions were cultured in 6-well plates (Costar) at different densities of viable cells with serum-free epithelial growth medium supplemented with a 1:50 dilution of B27 (Invitrogen), 20 ng/ml epidermal growth factor, 20 ng/ml basic fibroblast growth factor (BD), and 10 μg/ml heparin (Sigma). The number of spheroids was counted after 2 weeks. The resulting cells were counted using an Olympus IX81 high-resolution microscope (Olympus).

Flow cytometry
The cells were suspended to a density of 1 × 10^6 cells/ml, and 5 μL of Annexin V and propidium iodide (PI) staining solution were added to 300 μL of the cell suspension. After an incubation for 10–15 min at room temperature in the dark, stained cells were assayed and quantified using a FACSort Flow Cytometer (BD, San Jose, CA, USA). Each experiment was performed in triplicate and repeated at least twice.

Western blotting
Protein samples were extracted using cold RIPA lysis buffer containing protease inhibitor cocktail (Roche, Mannheim, Germany), and the protein concentration was determined using the BCA method. Equal amounts of protein lysates were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using a Bio-Rad system. Separated proteins were detected with the corresponding antibodies and visualized using enhanced chemiluminescence (ECL).

Coimmunoprecipitation
Cells were collected in cold PBS and lysed with immunoprecipitation (IP) lysis buffer (25 mM Tris•HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA, and 5% glycerol). Then, 2–5 μg of antibodies were added to the diluted cell lysates, and the mixtures were incubated overnight at 4 °C. The next day, the protein complexes were isolated with magnetic Protein A/G Dynabeads for 2 h at 4 °C with rotation. The bead-antibody-protein complexes were then washed 4 times with wash buffer (50 mM Tris (pH 7.4), 125 mM NaCl, 1 mM EDTA and 0.1% NP-40) and boiled before Western blot analysis.
Generation of the subcutaneous xenograft model in mice and establishment of PDX

All animal experimental protocols were performed in accordance with the National Institutes of Health Guidelines for the Care and Use of Experimental Animals.

Four-week-old BALB/c nude mice were purchased from the Animal Center of Guangxi Medical University (Nanning, China). For this experiment, $2 \times 10^6$ PDAC cells transfected with shDDIT4-AS1 or the negative control were subcutaneously injected into the flank region of the mice. The tumour volume was measured weekly and calculated as follows: $V = (\text{length} \times \text{width}^2)/2$. After four weeks, the tumours were excised and weighed.

Fresh tumor fragments were transplanted subcutaneously (s.c.) into the left flank of anaesthetized NOD scid gamma mice. Mice were observed for maximum 120 d and maintained under sterile and controlled conditions (22 °C, 50% relative humidity, 12 h light–dark cycle, autoclaved food and bedding, acidified drinking water). Tumor growth was measured in 2 dimensions with a caliper. Tumor volumes (TV) were determined by the formula: $TV = (\text{length} \times \text{width}^2)/2$. Tumors were routinely passaged at $TV = 1 \text{ cm}^3$. Xenograft material was snap frozen and stored at -80 °C or processed to formalin fixed, paraffin embedded (FFPE) blocks.

Fluorescence in situ hybridization (FISH)

PDAC cells grew on glass cover slips in 24-well plates overnight. The cells were fixed with paraformaldehyde and hybridized with DDIT4-AS probe was used to stain the nuclei. The results were observed under confocal microscopy.

Immunofluorescence (IF)

The cells were washed with PBS (Beyotime, C0221A) and then fixed with 4% paraformaldehyde (Sigma, V900894) for 30 min at room temperature. After being washed 3 times with PBS (Beyotime, C0221A), the cells were blocked in 10% donkey serum (Solarbio, S9100) for 10 min. The cells were subsequently incubated with primary antibodies specific overnight at 4 °C. The next day, the cells were washed with PBS, after which they were incubated with fluorescent-conjugated secondary antibodies (Beyotime, A0562), followed by DAPI (Beyotime, C1002). Images were captured by confocal microscopy.

DDIT4-AS1 RNA or its fragments and the UPF1 cDNA fragments

The full-length sense and antisense of DDIT4-AS1 RNA or its fragments (1–250, 251–500, 501–700, 401–847) were in vitro transcribed by using MEGAscript™ T7 Transcription Kit (Thermo Fisher Scientific, Waltham, MA, USA). The synthesized RNA probes were confirmed by RNA sequencing (RiboBio, Guangzhou, China).

Fragments encoding UPF1 amino acid residues were generated by PCR and inserted into a pcDNA3.1-Flag vector, which was synthesized by GenePharma (Shanghai, China). The details of PCR primers are listed in Supplementary materials.

Microarray analysis

We performed a microarray analysis using PDAC cells transfected with shDDIT4-AS1 or its negative control. Total RNA was extracted using an RNA simple Total RNA Kit (TIANGEN, DP419), and a NanoDrop One spectrophotometer (Thermo Fisher Scientific) was used to measure the RNA quantity. The microarray analysis was performed by Huayin Health Medical Group Co., Ltd. (Guangzhou, China). The obtained data were then subjected to KEGG and GO analyses. Cluster 3.0 and Java Tree View software were used to visualize heat maps.

RNA immunoprecipitation (RIP)

RIP was conducted with the Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, USA) according to the manufacturer’s instructions. Briefly, magnetic beads coated with 5 μg of specific antibodies were incubated with prepared cell lysates overnight at 4 °C. Then, the RNA–protein complexes were washed 6 times and incubated with proteinase K digestion buffer. RNA was finally extracted using phenol–chloroform RNA extraction methods. The relative RNA expression was determined using qPCR and normalized to the input.

Methylated RNA immunoprecipitation qPCR (MeRIP-qPCR)

The MeRIP-qPCR assay was performed to determine the level of m<sub>6</sub>A. Total intracellular RNA was extracted using TRIzol reagent. Anti-m<sub>6</sub>A antibodies or 9 anti-immunoglobulin G (IgG; Cell Signaling Technology) (3 μg) was first conjugated to Protein A/G magnetic beads and mixed with a 100 μg aliquot of total RNA in IP buffer containing RNase/protease inhibitors. The m<sub>6</sub>A-modified RNA was eluted twice with 6.7 mM N<sub>6</sub>-methyladenosine 5′-monophosphate sodium salt at 4 °C for 1 h. Subsequently, RT-qPCR analysis was performed to determine m<sub>6</sub>A enrichment. The methylated RNA was purified for further MeRIP sequencing by RiboBio (Guangzhou, China).

Northern blotting

Total RNA of BMDMs was extracted using TRI reagent (Sigma, USA). Biotin-labeled antisense and sense RNA probes (300 bp, 1,441 to 1,740 nt) were made in vitro using a HiScribe T7 Quick high-yield RNA synthesis kit.
were selected as CD133 positive and negative populations by IgG-bottom 2% corresponding to the most dimly stained cells by phycoerythrin (eBioscience, USA). Only the top 2%, however, yielded promising results revealing a significant reduction in m6A levels in lncRNA DDIT4-AS1 in cells with or without ALKBH5 overexpression. The results confirmed whether lncRNAs were demethylated by ALKBH5 and were involved in the malignant phenotype of PDAC cells by performing MeRIP sequencing.

**RNA pull-down assay**

A Pierce Magnetic RNA–Protein Pull-Down Kit (Thermo Fisher Scientific, 20,164) was used according to the manufacturer’s instructions. In brief, cell lysates were treated with RNAase-free DNAase I and incubated with biotinylated DDIT4-AS1 in the presence of streptavidin magnetic beads, which can capture the proteins/miRNAs potentially interacting with DDIT4-AS1. A Pierce™ RNA 3’ End Desthiobiotinylation Kit (Thermo, 20,163) was used for DDIT4-AS1 biotinylation labelling. Proteins and RNAs in the captured protein-RNA will be further analyzed.

**RNA stability**

For the transcriptional inhibitor actinomycin D (Millipore, Billerica, MA, USA). Cells were incubated with 10ug/mL actinomycin D at various time points. Real-time PCR was then performed to determine the mRNA expression. The relative amount of mRNA at 0 h following actinomycin D treatment was arbitrarily set to 1 h.

**Detection of CD133 expression using flow cytometry**

CD133+ cells were sorted by FACS using Anti-CD133/1-phycoerythrin (eBioscience, USA). Only the top 2%, corresponding to the most brightly stained cells or the bottom 2% corresponding to the most dimly stained cells were selected as CD133 positive and negative populations, respectively.

**Statistical analysis**

Statistical analyses were performed using SPSS 22.0 software. Comparisons between different groups were calculated using Student’s t-test, one-way ANOVA, or the Mann–Whitney U test. The clinical prognosis was assessed using the Kaplan–Meier analysis. Pearson's correlation analysis was performed to determine correlations. Statistical significance was set to \( p < 0.05 \). Data were recorded as means ± SD.

**Results**

**DDIT4-AS1 was regulated by ALKBH5 in an m6A-dependent manner**

As shown in our previous study, ALKBH5 overexpression sensitizes PDAC cells to chemotherapy [10]. We identified whether lncRNAs were demethylated by ALKBH5 and were involved in the malignant phenotype of PDAC cells by performing MeRIP sequencing in cells with or without ALKBH5 overexpression. The results revealed a significant reduction in m6A levels in 425 mRNAs and lncRNAs and a significant increase in m6A levels in 269 mRNAs and lncRNAs (Fig. 1a). Then, we screened differentially expressed lncRNAs in the TCGA-PDAC database, and 140 upregulated lncRNAs (LogFC ≥ 1) were identified in patients with PDAC. By comparing the two datasets listed above, an overlap of 2 lncRNAs was identified (Fig. 1b). Among these 2 genes, DDIT4-AS1 has rarely been studied and was selected for subsequent analysis.

Upon ALKBH5 overexpression, we observed a decrease in m6A peaks on DDIT4-AS1 based on MeRIP-seq (Fig. 1c). We further investigated whether DDIT4-AS1 was regulated by ALKBH5-mediated m6A modification by detecting DDIT4-AS1 expression and its m6A level in clinical PDAC samples. DDIT4-AS1 expression and m6A levels of DDIT4-AS1 were higher in PDAC tissues than in normal adjacent tissues (Fig. 1d and 1e). Then, we detected DDIT4-AS1 levels in PDAC cell lines (BxPC-3, AsPC-1, SW1990, CFPAC-1 and PANC-1) and a pancreatic ductal epithelial cell line (HPDE6-C7). The expression level of DDIT4-AS1 was upregulated in PDAC cell lines compared to pancreatic ductal epithelial cells (Fig. 1e). A similar result was obtained for the m6A analysis in BxPC-3, SW1990 and HPDE6-C7 cells (Fig. 1f). Furthermore, ALKBH5 knockdown increased the level of DDIT4-AS1 and its m6A modification in SW1990 cells (Fig. 1g and i); in contrast, ALKBH5 overexpression produced the opposite result in BxPC-3 cells (Fig. 1h and j).

We next searched for the m6A consensus motifs using STRAMP (www.cuilab.cn/sramp/) and identified the GGACU sequence at bases 539–543. We constructed Flag-tagged DDIT4-AS1 wt and mut plasmids (Fig. 1k). Depletion of ALKBH5 led to increased expression of wt DDIT4-AS1 but not mut DDIT4-AS1 (Fig. 1l), whereas overexpression of ALKBH5 led to decreased expression of wt DDIT4-AS1 but not mut DDIT4-AS1 (Fig. 1m). Then, we evaluated the level of the m6A modification in wt and mut DDIT4-AS1 using MeRIP-qPCR. As expected, the depletion of ALKBH5 increased the m6A level of wt DDIT4-AS1 but did not change the m6A level of mut DDIT4-AS1 (Fig. 1n). Based on these data, the m6A site was essential for ALKBH5-mediated DDIT4-AS1 expression. m6A readers, such as HuR and IGF2BP1, have been reported to recognize m6A sites and stabilize RNA. We explored how the m6A modification affects DDIT4-AS1 expression by knocking down HuR and IGF2BP1 in PDAC cells. Intriguingly, the depletion of HuR, but not IGF2BP1, significantly decreased the expression of DDIT4-AS1 (Fig. 1n, S1c). A RIP assay confirmed the direct interaction between HuR and DDIT4-AS1 in PDAC cells. In addition, the interaction between HuR and DDIT4-AS1 was impaired after ALKBH5
Fig. 1  DDIT4-AS1 was regulated by ALKBH5 in an m6A-dependent manner. a Volcano plot showing the differences in peaks between ctrl- and ALKBH5-overexpressing PDAC cells. Average E-score ≥ 6, |Log2(ctrl E-score/experimental E-score)| ≥ 1. b Venn diagram showing the numbers of overlapping IncRNAs between the differentially upregulated IncRNAs in TCGA-PDAC and the differentially expressed IncRNAs and mRNAs after ALKBH5 overexpression. c MeRIP-seq data showed the distribution of m6A peaks along DDIT4-AS1 in BxPC-3 cells transfected with the ALKBH5 plasmid compared to those transfected with the vector. d The m6A levels of DDIT4-AS1 from human PDAC tissues and normal adjacent tissues determined using MeRIP-qPCR. e The RNA levels of DDIT4-AS1 from PDAC cell lines and a pancreatic duct epithelial cell line (HPDE6-C7) were determined using qPCR. f MeRIP-qPCR analysis of m6A enrichment of DDIT4-AS1 in PDAC cell lines and pancreatic duct epithelial cell lines. g-h WB and RT-PCR analyses of ALKBH5 and DDIT4-AS1 levels in SW1990 cells transfected with the ALKBH5 siRNA and BxPC-3 cells transfected with the ALKBH5 plasmid. i-j MeRIP-qPCR analysis of the m6A levels in DDIT4-AS1 in SW1990 cells transfected with the ALKBH5 siRNA and BxPC-3 cells transfected with the ALKBH5 plasmid. k Putative m6A modification sites in the coding sequence of DDIT4-AS1 and synonymous mutations in DDIT4-AS1. l The relative expression levels of the DDIT4-AS1 RNA in SW1990 cells cotransfected with ALKBH5 siRNAs and DDIT4-AS1-WT or DDIT4-AS1-Mut. m MeRIP-qPCR analysis of the m6A levels in DDIT4-AS1 in SW1990 cells cotransfected with ALKBH5 siRNAs and DDIT4-AS1-WT or DDIT4-AS1-Mut. n WB and RT-PCR analyses of HuR and DDIT4-AS1 levels in BxPC-3 cells transfected with HuR siRNAs. o RIP analysis of the interaction of HuR with DDIT4-AS1 in BxPC-3 cells transfected with the ALKBH5 overexpression plasmid compared to cells transfected with the empty vector. Data are presented as the means ± SD of three independent experiments (*, P < 0.05; **, P < 0.01)
overexpression (Fig. 1o, S1d). Thus, HuR binds to DDIT4-AS1 to increase its expression in an m6A-dependent manner.

**DDIT4-AS1 is upregulated in PDAC and predicts shorter survival**

We assessed the expression of DDIT4-AS1 in PDAC by analysing the expression of DDIT4-AS1 in TCGA and GTEx databases; the results revealed that DDIT4-AS1 was significantly upregulated in PDAC tissues compared to normal tissues (Fig. 2a). This trend was further verified in randomly selected specimens using qRT-PCR (n = 40, Fig. 2b). In addition, the FISH results confirmed that DDIT4-AS1 was mainly located in the cytoplasm and that the level of DDIT4-AS1 was comparatively higher than that in normal tissues (Fig. 2c). Northern blot analysis with a specific RNA probe for DDIT4-AS1 showed that DDIT4-AS1 was detected at its expected size of 847 bp (Fig. 2d).

We evaluated the potential correlation between DDIT4-AS1 expression and clinicopathological features and found that DDIT4-AS1 was positively associated with the tumour size (p = 0.022) and tumour stage (p = 0.016, Table 1). The Kaplan–Meier analysis revealed that higher DDIT4-AS1 expression was associated with lower overall survival (OS) rates (p = 0.0038, Fig. 2e) and lower disease-free survival (DFS) rates for 269 patients with PDAC from TCGA (p = 0.026, Fig. 2f).

**DDIT4-AS1 maintains the stemness properties of PDAC cells**

CSCs are a small subpopulation of cells within a cancer and play a central role in cancer progression and therapy resistance, including PDAC [25]. ALKBH5 was reported to facilitate the development of several types of solid tumours and promote the self-renewal of relevant CSCs [26]. Therefore, we investigated the regulatory role of DDIT4-AS1 in PDAC stemness. Both gain- and loss-of-function studies were conducted. DDIT4-AS1 knockdown reduced the ability of PDAC cells to form primary and secondary spheroids (Fig. 3a-b, Fig. S1e-f). However, forced expression of DDIT4-AS1 increased primary and secondary spheroid formation (Fig. 3c-d). Next, the potential regulatory effect of DDIT4-AS1 on the expression of CSC markers was examined. DDIT4-AS1 silencing reduced
the expression of CSC markers; conversely, DDIT4-AS1 overexpression increased the expression of CSC markers (Fig. 3e, S1g). Consistent with the results for CSC markers, the proportions of CD133high PDAC cells were significantly decreased among DDIT4-AS1-depleted PDAC cells and increased among DDIT4-AS1-overexpressing PDAC cells (Fig. 3f-i, S1h-i).

In vivo serial dilution experiments were applied to assess the tumour-forming ability. Mice injected with DDIT4-AS1 knockdown BxPC-3 and PANC-1 cells exhibited an appreciably reduced tumour incidence, slightly reduced tumour growth and weights compared to control mice (Fig. 3j-k, S1j-n), suggesting that the CSC frequency was significantly reduced in DDIT4-AS1-depleted PDAC cells compared to control cells.

Table 1 Relationship between DDIT4-AS1 and clinicopathological parameters in 70 PADC patients

| Variables                  | All cases | DDIT4-AS1 expression | HR(95%CI) | χ2   | p*   |
|----------------------------|-----------|----------------------|-----------|------|------|
|                            | Low (n = 35) | High (n = 35) |             |      |      |
| Age(years)                 | ≥ 60      | 46                   | 25         | 21   | 1.667(0.615–4.519) | 0.163 | 0.314 |
|                            | 60        | 24                   | 10         | 14   | 1.259(0.491–3.230)  | 0.808 | 0.631 |
| Gender                     | Male      | 38                   | 20         | 18   | 0.552(0.211–1.446)  | 0.082 | 0.225 |
|                            | Female    | 32                   | 15         | 17   | 1.833(0.614–5.471)  | 0.000 | 0.016 |
| Tumor size(cm)             | ≤ 3       | 23                   | 16         | 7    | 3.368(1.164–9.744)  | 0.001 | 0.022 |
|                            | ≥ 3       | 47                   | 19         | 28   | 0.552(0.211–1.446)  | 0.082 | 0.225 |
| Tumor differentiation      | Well/Moderate | 41                   | 18         | 23   | 1.833(0.614–5.471)  | 0.082 | 0.225 |
|                            | Poor      | 29                   | 17         | 12   | 0.552(0.211–1.446)  | 0.000 | 0.016 |
| Lymph node invasion        | Absent    | 52                   | 28         | 24   | 1.833(0.614–5.471)  | 0.082 | 0.225 |
|                            | Present   | 18                   | 7          | 11   | 0.552(0.211–1.446)  | 0.000 | 0.016 |
| TNM stage                  | I-II      | 32                   | 21         | 11   | 3.273(1.224–8.748)  | 0.000 | 0.016 |
|                            | III-IV    | 38                   | 14         | 24   | 0.000                 |      |      |

* Probability, p, from χ² test

DDIT4-AS1 suppresses the chemosensitivity of PDAC cells to GEM

Then, we investigated whether DDIT4-AS1 manipulates the chemosensitivity of PDAC cells. Ectopic suppression of DDIT4-AS1 sensitized PDAC cells to GEM, as reflected by the reduced colony formation ability (Fig. 4a-b, S2a-b). In contrast, overexpression of DDIT4-AS1 compromised GEM-induced suppression of colony formation (Fig. 4c-d). Except for GEM, we also tested the chemosensitivity of cancer cells to paclitaxel. The combination of shDDIT4-AS1 with paclitaxel had similar inhibitory effects on tumour growth, but weaker than the combination effects of shDDIT4-AS1 with GEM (Fig. S2c-d).

We next evaluated the role of DDIT4-AS1 in regulating GEM sensitivity in vivo by subcutaneously injecting equal amounts of control or knockdown PDAC cells (2 × 10⁶) into mouse flanks. After one week, the nude mice were treated with 60 mg/kg GEM twice a week. Tumour growth in each group was monitored for 26 days. The DDIT4-AS1 knockdown group treated with GEM exhibited substantial reductions in tumour weight and growth (Fig. 4e-f). Moreover, the combination of DDIT4-AS1 knockdown and GEM treatment resulted in weak staining for Ki67 and strong staining for Caspase-3 (Fig. 4g, S2e). Overall, these data suggested...
that the tumours derived from PDAC cells with DDIT4-AS1 knockdown were more sensitive to GEM than those derived from vector-transfected PDAC cells.

DDIT4-AS1 regulates stemness and chemosensitivity by activating the mTOR pathway

We explored the potential mechanisms by which DDIT4-AS1 regulates stemness and chemosensitivity...
Fig. 4 DDIT4-AS1 suppresses the chemosensitivity of PDAC cells to GEM. a-b Colony formation in shDDIT4-AS1-silenced PDAC cells after treatment with 10 nM GEM. c-d Colony formation in DDIT4-AS1 overexpression plasmid-transfected PDAC cells after treatment with 10 nM GEM. e Representative images of xenograft tumours in nude mice after different treatments. GEM was injected intraperitoneally twice per week for 26 days. The combination of shDDIT4-AS1 with GEM exerted stronger inhibitory effects on tumour growth. f The tumour growth curves of each group of mice are summarized. g IHC staining for Ki67 and Caspase-3 expression in different groups. Data are presented as the means ± SD of three independent experiments (*, *P < 0.05; **, *P < 0.01)
by performing RNA sequencing (RNA-seq) to identify the differentially expressed genes upon DDIT4-AS1 knockdown, and 547 upregulated genes and 470 downregulated genes were identified (|LogFC| ≥ 1, P < 0.05, Fig. 5a). KEGG enrichment revealed that the significantly enriched pathways include TNF, ErbB and mTOR pathway (Fig. 5b). We supplemented Etanercept and Dacomitinib to DDIT4-AS1-overexpression-BxPC-3 cells and found that the TNF or ErbB signaling pathway did not have obvious effects on the stemness of pancreatic cancer cells (Fig. S2f-i). Multiple studies have reported that the mTOR pathway may contribute to cancer stemness maintenance [27, 28], chemoresistance [29–31] and tumour development [32]. The GSEA results showed that the differentially expressed gene sets were significantly related to the mTOR pathway (Fig. 5c). Next, we evaluated whether mTOR pathway was involved in stemness regulation mediated by DDIT4-AS1. The levels of proteins in the mTOR signalling pathway were examined using western blotting, and the results showed that DDIT4-AS1 knockdown inhibited mTOR pathway activity, as reflected by the decreased phosphorylation of mTOR, ULK1 and p70S6K. Meanwhile, DDIT4-AS1 overexpression activated the mTOR pathway (Fig. 5d). Then, we assessed whether the mTOR pathway was required for the DDIT4-AS1-mediated regulation of stemness and chemosensitivity. PDAC cells overexpressing DDIT4-AS1 were exposed to rapamycin to inhibit mTOR pathway activity (Fig. 5e). As expected, the treatment of cells with rapamycin restored the effects of DDIT4-AS1 overexpression on stemness marker expression, spheroid formation ability and chemosensitivity to GEM (Fig. 5f-g). These results indicate that DDIT4-AS1 promotes stemness and inhibits chemosensitivity by activating the mTOR pathway.

DDIT4-AS1 recruits UPF1 to destabilize DDIT4 and activate the mTOR pathway

The cognate sense transcript of DDIT4-AS1 is DDIT4, which has been identified as a negative regulator of the mTOR signalling pathway [33]. Interestingly, when we referred to the gene set of the mTOR signalling pathway, DDIT4 was significantly upregulated upon DDIT4-AS1 knockdown. The WB results indicated that DDIT4 silencing reactivated the mTOR pathway that was suppressed by DDIT4-AS1 depletion (Fig. 6a), whereas DDIT4 overexpression abolished the activation of the mTOR pathway caused by DDIT4-AS1 overexpression (Fig. 6b). Compared to the patients with lower levels of DDIT4-AS1, patients with high levels of DDIT4-AS1 showed higher levels of p-mTOR, CD133 and CD44 IHC staining and lower levels of ALKBH5 and DDIT4 (Fig. 6c, S2). The IHC staining of subcutaneous tumour tissues revealed decreased p-mTOR and increased DDIT4 levels in the sh-DDIT4-AS1 group compared with the shCtrl group (Fig. S2k-l). Based on these results, DDIT4 mediates the regulation of the mTOR pathway by DDIT4-AS1. There have been studies demonstrated that the effects of DDIT4 on mTOR was dependent on TSC complex, especially TSC2 [34, 35]. In order to verify above mechanism, TSC2 was knockdown or overexpression with siRNA or overexpression plasmid. The effects of DDIT4-AS1 and DDIT4 on mTOR were abrogated in cells transfected with TSC2 siRNAs or overexpression plasmid (Fig. S2m-n), suggesting the function of DDIT4 on mTOR required TSC complex.

We next examined the mechanism by which DDIT4-AS1 regulates DDIT4. FISH staining showed that DDIT4-AS1 was located in the cytoplasm of PDAC cells (Fig. 6d). DDIT4-AS1 knockdown resulted in an increase in the half-life of the DDIT4 mRNA (Fig. 6e), whereas DDIT4-AS1 overexpression led to a decreased half-life of the DDIT4 mRNA (Fig. 6f), suggesting that DDIT4-AS1 destabilizes the DDIT4 mRNA. Then, we performed an RNA pull-down assay using a biotinylated DDIT4-AS1 oligonucleotide, and endogenous DDIT4 mRNA did not coprecipitate with DDIT4-AS1; therefore, we hypothesized that some protein(s) may mediate the regulatory effect of DDIT4-AS1 on the DDIT4 mRNA. We used the starBase database to predict the proteins that interact with DDIT4-AS1 and DDIT4, and UPF1 and DGCR8 were identified as potential interactors (Fig. 6g). We selected UPF1, which may participate in mRNA degradation, for further validation. Knockdown of UPF1 in DDIT4-AS1-overexpressing cells rescued the decreased expression of the DDIT4 mRNA (Fig. 6h). In contrast, overexpression of UPF1 in DDIT4-silenced cells exerted the opposite effects (Fig. S2o), suggesting that UPF1...
Fig. 5 (See legend on previous page.)
facilitated the DDIT4-AS1-mediated degradation of DDIT4.

We evaluated the interaction between DDIT4-AS1 and UPF1 by performing IF colocalization assays and showed that DDIT4-AS1 and UPF1 colocalized in the cytoplasm of PDAC cells (Fig. 6i). RIP assays with an UPF1 antibody showed that UPF1 bound specifically to DDIT4-AS1 (Fig. S2p). Then, we detected the binding sites for DDIT4-AS1 with UPF1. We constructed one biotinylated full-length anti-sense DDIT4-AS1 probe (F1), four biotinylated fragments of DDIT4-AS1 probes (F2-F5) and one full-length sense DDIT4-AS1 probe (F6) to pull down UPF1 in PDAC cell lysates (Fig. 6j). The fragment consisting of bases 701 to 847 of DDIT4-AS1 was crucial for the interaction with UPF1, whereas other fragments did not interact with UPF1 (Fig. 6k). As previously reported, UPF1 contains two major domains: the SQ domain near the C-terminus and the CH domain near the N-terminus (Fig. 6l). We identified the binding region in UPF1 by cloning a series of Flag-tagged UPF1 constructs (P1: 1–115 aa, P2: 116–294 aa, P3: 295–914 aa, P4: 915–1118 aa, and P5: 1–1118 aa) (Fig. 6m). RIP assays were performed with an anti-Flag antibody and revealed that both P4 and P5 interacted with DDIT4-AS1 (Fig. 6n), suggesting that the SQ domain of UPF1 is required for the interaction with DDIT4-AS1.

Then, we further verified whether the DDIT4 mRNA bound to UPF1. We performed RIP in PDAC cells and found that UPF1 bound to the DDIT4 mRNA (Fig. S3a). We determined the region in which DDIT4 participates in the interaction by constructing a Flag-tagged expression vector including the DDIT4 coding sequence with the 3′UTR (DDIT4 CDS-3′UTR) or the CDS alone (DDIT4 CDS) and cotransfected PDAC cells with the UPF1 siRNA or overexpression plasmid. UPF1 knockdown or overexpression negatively regulated the expression of DDIT4 in PDAC cells transfected with the DDIT4 CDS-3′UTR. However, its expression was not altered in cells transfected with the DDIT4 CDS alone (Fig. S3b–i), suggesting that the 3′UTR is indispensable for the UPF1-mediated regulation of DDIT4.

**DDIT4-AS1 prevents the binding of SMG5 and PP2A to UPF1 and inhibits its phosphorylation**

Phosphorylation of UPF1 is required for its functions and plays an important role in regulating RNA stability. Notably, the depletion of DDIT4-AS1 induced the accumulation of phospho-UPF1 without affecting the total amount of UPF1 (Fig. 7a). However, DDIT4-AS1 overexpression exerted the opposite effects (Fig. 7b). According to a previous study, the SMG5 interaction with PP2A is required for the dephosphorylation of UPF1 in an evolutionarily conserved manner [36]. We treated PDAC cells with okadaic acid (OA, a potent inhibitor of PP2A) or FTY710 (an activator of PP2A). OA treatment resulted in an increase in p-UPF1 levels, coincident with a decrease in DDIT4 mRNA expression and stability (Fig. 7c–e); in contrast, FTY710 produced the opposite changes in p-UPF1 level, DDIT4 mRNA expression and stability (Fig. 7c–e). We further evaluated the underlying mechanism by performing immunoprecipitation in cells with DDIT4-AS1 knockdown and overexpression, and the results showed that SMG5 and PP2A interacted with UPF1 and phospho-UPF1. This interaction was attenuated by DDIT4-AS1 knockdown (Fig. 7f) and enhanced by exotic expression of DDIT4-AS1 (Fig. 7g). Then, we transiently co-expressed epitope-tagged PP2A and SMG5 in 293 T cells treated with nonbiotinylated DDIT4-AS1, finding that nonbiotinylated DDIT4-AS1 suppresses the interaction of SMG5 and PP2A with UPF1 and phospho-UPF1 in a dose-dependent manner (Fig. 7h).

**The combination of DDIT4-AS1 knockdown and GEM exerts synergistic effects on PDX models**

We conducted an in vivo evaluation of the efficacy of the combination of DDIT4-AS1 knockdown and GEM therapy in PDX models, which were successfully established in our lab. The nude mice were divided into three groups: DDIT4-AS1 knockdown (1), GEM therapy (2) and DDIT4-AS1 knockdown and GEM therapy (3). The mice were treated with GEM or DDIT4-AS1 siRNA for 1 week. The combination of DDIT4-AS1 knockdown and GEM significantly inhibited tumor growth (Fig. 8a). The combination of DDIT4-AS1 knockdown and GEM also prolonged the survival of the mice (Fig. 8b). The combination of DDIT4-AS1 knockdown and GEM significantly decreased the level of DDIT4 mRNA in the tumor tissues (Fig. 8c). The combination of DDIT4-AS1 knockdown and GEM significantly decreased the level of CD133 and CD44 in PDAC tissues with higher or lower levels of DDIT4-AS1 formed by shDDIT4-AS1 or control cells (Fig. 8d). The combination of DDIT4-AS1 knockdown and GEM significantly decreased the expression of ALKBH5, DDIT4, p-mTOR, phospho-UPF1 and phospho-UPF1 in PDAC tissues with lower levels of DDIT4-AS1 (Fig. 8e). These results suggest that the combination of DDIT4-AS1 knockdown and GEM exerts synergistic effects on PDX models.
into 4 groups ($n=5$ per group) and received an intra-tumour injection of an empty vector (Vec) or lentiviral-shDDIT4-AS1 (shDDIT4-AS1); meanwhile, 2 of 4 groups also received an intraperitoneal injection of GEM. The combination of shDDIT4-AS1 with GEM exerted a stronger inhibitory effect on tumour growth and weight than any individual treatment (Fig. 8a-c). IHC staining for DDIT4 and p-mTOR showed that DDIT4-AS1 silencing increased DDIT4 expression and reduced p-mTOR expression (Fig. 8d, S3). Moreover,
the combination of shDDIT4-AS1 with GEM reduced proliferation and increased apoptosis compared with the other groups, as determined using Ki67 and Caspase-3 staining (Fig. 8d, S3j). Taken together, virus-mediated DDIT4-AS1 silencing increased the chemosensitivity of PDAC cells to GEM through the DDIT4-mediated mTOR pathway.

Discussion

The m^6^A modification is one of the most common epigenetic methylation modifications and is involved in almost all stages of RNA metabolism, including RNA splicing, export, stability, and translation [37]. In addition to mRNAs, noncoding RNAs, such as lncRNAs, are also substrates of m^6^A modification. In the present study, we found that ALKBH5 mediated m^6^A demethylation of DDIT4-AS1 and that HuR stabilized DDIT4-AS1 by binding to m^6^A sites. HuR is recognized as an
m6A reader, and a previous study reported that HuR was recruited to m6A-containing RNA and contributed to RNA stabilization [38], consistent with our study. Our study also revealed that DDIT4-AS1 was upregulated in PDAC tissues and that increased DDIT4-AS1 levels predicted poor clinical outcomes. Therefore, DDIT4-AS1 may serve as a potential diagnostic and prognostic biomarker (Fig. 9).

DDIT4-AS1 is functionally related to controlling the stemness properties and chemosensitivity of PDAC cells. Overexpression of DDIT4-AS1 enhances stemness and suppresses chemosensitivity to GEM. We explored the
underlying mechanism by performing RNA-seq to examine the differentially expressed genes, and the mTOR pathway was identified as an enriched pathway. mTOR is a 289 kDa serine/threonine kinase belonging to the PI3K-related kinase family [39]. mTOR encompasses two functionally distinct protein complexes: mTORC1 and mTORC2 [40]. The serine/threonine kinases p70S6K1 [41] and ULK1 [42] are the most well-known downstream targets of mTORC1. mTOR is frequently dysregulated in various human cancers and plays a crucial role in multiple biological processes, including stemness and chemosensitivity regulation [43–45]. For example, miR-135b silencing inactivates the AKT/mTOR pathway and ultimately results in the inhibition of self-renewal and tumour growth of pancreatic cancer stem cells [46]. PRKAR1B-AS2 promotes tumour growth and confers chemoresistance by modulating the PI3K/AKT/mTOR pathway in ovarian cancer [47]. In the present study, DDIT4-AS1 knockdown decreased p-mTOR, p-p70S6K and p-ULK1 levels to inhibit the mTOR pathway. Rapamycin restored the effects of DDIT4-AS1 overexpression on stemness and chemosensitivity to GEM in pancreatic cancer. Thus, the effect of DDIT4-AS1 depends on the mTOR signalling pathway.

Antisense lncRNAs were identified to have a close relationship with homologous sense genes in a natural physiological state [48]. Some antisense lncRNAs regulate sense mRNAs. KRT7-AS, which functions as an onco-gene in gastric cancer, was speculated to form a complementary complex with its sense KRT7 mRNA and affect KRT7 mRNA stability [49]. SATB2-AS1 is the cognate antisense transcript of SATB2, and SATB2-AS1 activates SATB2 in cis by recruiting WDR5 and GADD45A to the SATB2 promoter region and inhibits the progression of colorectal cancer [50]. As DDIT4 is the sense mRNA of DDIT4-AS1, we evaluated whether DDIT4 was involved in the regulation of mTOR activation by DDIT4-AS1. DDIT4 silencing reactivated the mTOR pathway that was suppressed by DDIT4-AS1 depletion, whereas DDIT4 overexpression abolished the activation of the mTOR pathway caused by DDIT4-AS1 overexpression, indicating that DDIT4 mediates the regulation of the mTOR pathway by DDIT4-AS1.

![Diagram](Created with BioRender.com)
In terms of the relationship between DDIT4-AS1 and DDIT4, the RNA pull-down results suggested that DDIT4-AS1 did not directly interact with DDIT4. Therefore, we conducted a bioinformatics analysis to determine whether some regulatory proteins were involved in this process, and UPF1 was identified as a possible molecule. UPF1 is an RNA helicase belonging to helicase superfamily 1 that has two major domains: an SQ domain near the C-terminus and a CH domain near the N-terminus. UPF1 is a well-known key factor involved in nonsense-mediated mRNA decay (NMD), a conserved mRNA surveillance pathway that degrades mRNA containing a premature termination codon [51]. For example, UPF1 directly interacts with the STAU1 mRNA to promote its degradation [52]. In our study, we confirmed that knockdown of UPF1 rescued the decreased expression of the DDIT4 mRNA induced by DDIT4-AS1 overexpression and vice versa. The interaction of UPF1 with DDIT4-AS1 and DDIT4 was validated by RIP and RNA pulldown, indicating that UPF1 mediated the regulatory effect of DDIT4-AS1 on the DDIT4 mRNA.

Previous studies revealed that UPF1 phosphorylation plays an important role in promoting its cellular activities and facilitates the binding of other factors involved in NMD and other processes to it [53]. Interestingly, DDIT4-AS1 suppressed the phosphorylation of UPF1 without affecting the amount of UPF1 protein in the present study. However, the underlying mechanism is unknown. SMG1, SMG5, SMG6 and SMG7 are essential NMD factors that have been implicated in the regulation of UPF1 phosphorylation [54]. Among these NMD factors, SMG5 directly recruits PP2A phosphatases via the C-terminal PIN domain and results in dephosphorylation of UPF1 [53]. In our study, we confirmed that SMG5 and PP2A coimmunoprecipitated with UPF1, and treating PDAC cells with a potent inhibitor or activator of PP2A results in an increase or decrease in p-UPF1 levels, respectively, consistent with previous reports. Further observations revealed that this interaction between SMG5, PP2A and UPF1 was attenuated by DDIT4-AS1 knockdown and enhanced by ectopic expression of DDIT4-AS1, which supports the hypothesis that DDIT4-AS1 dissociates SMG5 and PP2A from UPF1 and enhances NMD by increasing UPF1 phosphorylation. It was also reported that SMG5 can bind to SMG7 to form a complex that preferentially binds to phosphorylated UPF1 [36], SMG6 had also been proposed to compete with the SMG5:SMG7 complex for binding to phosphorylated UPF1 [55]. Whether SMG7 and SMG6 are involved in regulation of UPF1 phosphorylation by DDIT4-AS1 is unknown and remains to be clarified in our future studies.

Conclusions
In conclusion, DDIT4-AS1 is amplified, overexpressed, and stabilized by ALKBH5 and HuR in PDAC cells. DDIT4-AS1, which functions as an oncogene, significantly promotes PDAC stemness and suppresses chemosensitivity to GEM. DDIT4-AS1 physically interacts with UPF1 and covers the binding sites for SMG5 and PP2A to promote UPF1 phosphorylation, the degradation of the DDIT4 mRNA and activation of the mTOR pathway. Treatment with the DDIT4-AS1 shRNA combined with GEM significantly increased the antitumour activity of PDAC in a PDX-based model. The discovery of DDIT4-AS1 provides insights into PDAC carcinogenesis and may facilitate the development of precise approaches for cancer screening and treatment.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12943-022-01647-0.

Abbreviations
PDX: Patient-derived xenograft; GEM: Gemcitabine; CSC: Cancer stem cell; m6A: N6-methyladenosine; PDAC: Pancreatic ductal adenocarcinoma; DDIT4/REDD1: DNA damage-inducible transcript 4; HuR: Human antigen R; ATCC: American Type Culture Collection; FBS: Fetal bovine serum; qRT-PCR: Quantitative real-time polymerase chain reaction; cDNA: Complementary DNA; IHC: Immunohistochemistry; IP: Immunoprecipitation; TCGA: The Cancer Genome Atlas; GTEx: Genotype-Tissue expression; OS: Overall survival; DFS: Disease-free survival; FACS: Fluorescence-activated cell sorting; GO: Gene ontology; GSEA: Gene set enrichment analysis; NMD: Nonsense-mediated mRNA decay.

Additional file 1: Figure S1. a. The RNA levels of DDIT4-AS1 in 9 paired human PDAC tissues and normal adjacent tissues. b. The relative RNA levels of DDIT4-AS1 in BxPC-3 cells cotransfected with the ALKBH5 overexpression plasmid and DDIT4-AS1-WT or DDIT4-AS1-Mut. cWB and RT-PCR analyses of IGF2BP1 and DDIT4-AS1 levels in BxPC-3 cells transfected with IGF2BP1 siRNAs. d. qRT-PCR was used to determine the level of DDIT4-AS1 immunoprecipitated by the anti-HuR antibody. e-f. Representative images of sphere formation induced by the transfection of shDDIT4-AS1 into Panc-1 cells. The surviving colonies were measured by calculating the fold changes. g. The expression levels of CSC markers were examined in DDIT4-AS1-silenced Panc-1 cells using Western blotting. h. Flow cytometry was performed to assess the percentage of CD133+ cells among PANC-1 cells with or without DDIT4-AS1 depletion. i. Flow cytometry was performed to assess the percentage of CD133+ cells among BxPC-3 cells with or without DDIT4-AS1 depletion. j. Flow cytometry was performed to assess the percentage of CD133+ cells among BxPC-3 cells with or without DDIT4-AS1 depletion. k. Flow cytometry was performed to assess the percentage of CD133+ cells among BxPC-3 cells with or without DDIT4-AS1 depletion. l. Flow cytometry was performed to assess the percentage of CD133+ cells among BxPC-3 cells with or without DDIT4-AS1 depletion. m. Flow cytometry was performed to assess the percentage of CD133+ cells among BxPC-3 cells with or without DDIT4-AS1 depletion. n. Flow cytometry was performed to assess the percentage of CD133+ cells among BxPC-3 cells with or without DDIT4-AS1 depletion. o. Flow cytometry was performed to assess the percentage of CD133+ cells among BxPC-3 cells with or without DDIT4-AS1 depletion. p. Flow cytometry was performed to assess the percentage of CD133+ cells among BxPC-3 cells with or without DDIT4-AS1 depletion. q. Flow cytometry was performed to assess the percentage of CD133+ cells among BxPC-3 cells with or without DDIT4-AS1 depletion.
DDIT4-AS1 depletion and treated with 60 mg/kg GEM twice a week. The Ki67 and Caspase-3 expression were evaluated by IHC staining. h-i Representative images of sphere formation in DDIT4-AS1-depleted BxPC-3 cells with or without etanercept treatment. The sphere formation was measured by calculating the fold changes. h-i The levels of Ki67, DDIT4 and p-mTOR were assessed in the shCtrl and shDDIT4-AS1#1 groups using IHC. m-n WB analysis of TSC2, DDIT4 and mTOR pathway-related proteins in DDIT4-AS1-depleted BxPC-3 cells transfected with TSC2 siRNA and DDIT4-depleted SW1990 cells transfected with TSC2 overexpression plasmid. o The level of DDIT4 mRNA was examined in DDIT4-AS1 knockdown BxPC-3 cells with or without UPF1 overexpression using qRT-PCR. qRT-PCR was used to determine the level of DDIT4-AS1 immunoprecipitated by the anti-UPF1 antibody. Data are presented as the means ± SD of three independent experiments (*, \( P < 0.05 \); **, \( P < 0.01 \)).

**Additional file 3: Figure S3.** a-q RT-PCR was performed to determine the level of the DDIT4 mRNA immunoprecipitated by the anti-UPF1 antibody. b-c qRT-PCR analysis of Flag-DDIT4 levels in BxPC3 cells expressing Flag-DDIT4 with the DDIT4 CDS-3’UTR or DDIT4 CDS and treated with control or UPF1 siRNAs. The expression of the forward primer corresponds to the 3’ flag vector. d-e WB analysis of Flag-DDIT4 levels in BxPC3 cells expressing Flag-DDIT4 with the DDIT4 CDS-3’UTR or DDIT4 CDS and treated with control or UPF1 siRNAs. f-g qRT-PCR analysis of Flag-DDIT4 levels in SW1990 cells expressing Flag-DDIT4 with the DDIT4 CDS-3’UTR or DDIT4 CDS and treated with control or UPF1 siRNAs. h-i WB analysis of Flag-DDIT4 levels in SW1990 cells expressing Flag-DDIT4 with the DDIT4 CDS-3’UTR or DDIT4 CDS and treated with control or UPF1 siRNAs. j The levels of K67, Caspase-3,DDIT4 and p-mTOR were assessed in different groups using IHC. Data are presented as the means ± SD of three independent experiments (*, \( P < 0.05 \); **, \( P < 0.01 \)).

**Additional file 4.** Supplementary materials.

Acknowledgements
Not applicable.

Authors’ contributions
Y.Z., X.L. and T.W. designed the experiments, analyzed data and wrote the manuscript. S.L. and Z.W. contributed to experiments in vivo. Y.Y. and W.L. performed the experiments in vitro. H.W. helped perform the experiments and analyze the data. B.T. conceived the project, designed and supervised the research. All authors reviewed and approved the manuscript.

Funding
This research was supported in part by The National Natural Science Foundation of China (No. 82072729), the Natural Science Foundation of Jiangsu (BK20211606).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
This study was approved by the Ethics Committee of The First Affiliated Hospital of Guangxi Medical University.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Huaniu West Road, Hexi District, 300060 Tianjin, China. 2 Department of General Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, Jiangsu, People’s Republic of China. 3 Key Laboratory of Basic and Clinical Application Research for Hepatobiliary Diseases of Guangxi, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.

Received: 15 June 2022 Accepted: 25 August 2022
Published online: 02 September 2022

References
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7–33.
2. Oettlie H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–81.
3. Hermann PC, Huber SL, Herleier T, Aicher A, Ellwart JW, Guba M, et al. Distinct Populations of Cancer Stem Cells Determine Tumor Growth and Metastatic Activity in Human Pancreatic Cancer. Cell Stem Cell. 2007;1:313–23.
4. Lee CJ, Dosch J, Simeone DM. Pancreatic cancer stem cells. J Clin Oncol. 2008;26:2806–12.
5. Shi H, Wei J, He C, Where, When, and How: Context-Dependent Functions of RNA Methylation Writers, Readers, and Erasers. Mol Cell. 2019;74:640–50.
6. Deng X, Su R, Weng H, Huang H, Li Z, Chen J. RNA N6-methyladenosine modification in cancers: current status and perspectives. Cell Res. 2018;28:507–17.
7. Huang H, Wang Y, Kandpal M, Zhao G, Cardenas H, Ji Y, et al. FTO-Dependent Modification of lncRNA Pvt1 governs epidermal stemness. EMBO J. 2021;40:e106276.
8. Zhang C, Samanta D, Lu H, Bullen JW, Zhang H, Chen J, et al. Hypoxia induces the breast cancer stem cell phenotype by HIP-dependent and ALKBH5-mediated m7A-demethylation of NANOG mRNA. Proc Natl Acad Sci USA. 2016;113:E2047–56.
9. Tang B, Yang Y, Kang M, Wang Y, Wang Y, Bi Y, et al. m6A demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating TSG4 signaling. Mol Cancer. 2020;19:3.
10. Davies BM, Yanez Touzet A, Mowforth OD, Lee KS, Khan D, Furlan JC, et al. Development of a core measurement set for research in degenerative cervical myelopathy: a study protocol (AD Spine RECORD-DCM CMS). BMJ Open. 2022;12:e060436.
11. Lin L, Stringfield TM, Shi X, Chen Y. Arsenite induces a cell stress-response gene, RTP801, through reactive oxygen species and transcription factors Elk-1 and CCAAT/enhancer-binding protein. Biochem J. 2005;392:93–102.
12. Tirado-Hurtado I, Fajardo W, Pinto JA. DNA Damage Inducible Transcription 4 Gene: The Switch of the Metabolism as Potential Target in Cancer. Front Oncol. 2018;8:106.
13. Brugarolas J. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004;18:2893–904.
14. Marshall DC, Taras ES, Ali B, Bloom J, Torres MA, Kahn JM. Female erectile tissues and sexual dysfunction after pelvic radiotherapy: A scoring review. CA Cancer J Clin. 2022;72(6):335–9.
15. DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 2008;22:239–51.
16. Yoshida T, Mett I, Bhunia AK, Bowman J, Perez M, Zhang L, et al. Rptpα, a suppressor of mTOR signaling, is an essential mediator of cigarette smoke-induced pulmonary injury and emphysema. Nat Med. 2010;16:767–73.
18. Miao Z-F, Sun J-X, Adkins-Testani M, Pang M-J, Zhao J-H, Wang X, et al. N6-Methylandenosine-Related lncRNA Signature Is a ROS suppresses tumorigenesis. Proc. Natl Acad Sci U S A. 2010;107:4675–80.

19. Ho KH, Chen PH, Chou CM, Shih CM, Lee YT, Cheng CH, et al. A Key Role of DNA Damage-Inducible Transcript 4 (DDIT4) Connects Autophagy and GLUT3-Mediated Steatosis To Desensitize Temozolomide Efficacy in Glioblastomas. Neurotherapeutics. 2020;17:1212–27.

20. Schwarzer R, Tondera D, Arnold T, Giese K, Kleppel A. J. REDD1 integrates hypoxia-mediated survival signalling downstream of phosphatidylinositol 3-kinase. Oncogene. 2005;24:1138–49.

21. Ben Sahra I, Regazzi C, Robert G, Laurent K, Le Marchand-Brustel Y, Aubeger P, et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 2011;71:4366–72.

22. Qiao S, Koh SB, Vivekanandan V, Salunke D, Patra KC, Zaganjer E, et al. REDD1 loss reprograms lipid metabolism to drive progression of RAS mutant tumors. Genes Dev. 2020;34:75–1–66.

23. Krappinger JC, Bonstingl L, Pansy K, Sallinger K, Wreglesworth NI, Grinnings L, et al. Non-coding Natural Antisense Transcripts: Analysis and Application. J Biotechnol. 2021;340:75–101.

24. Kumar B, Ahmad R, Sharma S, Gowrikumar S, Primeaux M, Rana S, et al. PhosphoS3 Inhibition Promotes Sensitivity to Colon Cancer Therapy by Inhibiting Cancer Stem Cells. Cancers. 2021;13:9.2168.

25. Shen C, Sheng Y, Zhu AC, Robinson S, Jiang X, Dong L, et al. RNA Demethylase ALKBH4 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid Leukemia. Cell Stem Cell. 2020;27(11):64-80. e9.

26. Seo HS, Akiyama Y, Lee S-E, Shimada S, Jiang SJ. Loss of miR-100 and miR-125b results in cancer stem cell properties through IGFl2 upregulation in hepatocellular carcinoma. Sci Rep. 2020:10:21412.

27. Wang K, Huang W, Sang X, Wu X, Shan Q, Tang D, et al. Atractylenolide I inhibits colorectal cancer cell proliferation by affecting metabolism and stemness via AKT/mTOR signaling. Phytomedica. 2020;68:153191.

28. Li Z, Li C, Wu Q, Tu Y, Wang C, Yu X, et al. MDA5 enhances breast cancer progression and reduces euripulin sensitivity through the AKT/AMPK/mTOR pathway. Cell Death Dis. 2021;12:97.

29. Qi C, Su W, Shen N, Qi X, Wu X, Wang K, et al. MNAT1 promotes proliferation and the chemo-resistance of osteosarcoma cell to cisplatin through regulating PI3K/Akt/mTOR pathway. BMC Cancer. 2020;20:1187.

30. Feng M, Xiong G, Cao Z, Yang G, Cheng S, Qiu J, et al. ALT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer. J Exp Clin Cancer Res. 2018;37:274.

31. Xi S, Cai H, Lu J, Zhang Y, Yu Y, Chen F, et al. The pseudogene PRELID1 promotes glioma progression through the hnnHPFH1-Akt/mTOR axis. Oncogene. 2021;40(24):4653–67.

32. Xu Q, Gushui M, Li D, Bai F, Fang J, Zhang G, et al. IncRNA CD sat2 facilitates autophagy and apoptosis via the miR-330-3p-DDIT4/mTOR axis in cerebral ischemia-reperfusion injury. Aging. 2021;13:1135–35.

33. Brugairous J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004;18:2893–904.

34. Jin HO, Seo SK, Kim YS, Woo SH, Lee KH, Yi JY, et al. TXNIP potentiates PI3KCA Inhibition Promotes Sensitivity to Colon Cancer Therapy by Inhibiting Cancer Stem Cells. Cancers. 2021;13:9:2168.

35. Jin HO, Seo SK, Kim YS, Woo SH, Lee KH, Yi JY, et al. TXNIP potentiates PI3KCA Inhibition Promotes Sensitivity to Colon Cancer Therapy by Inhibiting Cancer Stem Cells. Cancers. 2021;13:9:2168.

36. Ohnishi T, Yamashita A, Kashima I, Schell T, Anders KR, Grimson A, et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 2011;71:4366–72.

37. Zhang P, Liu G, Lu L. N6-Methyladenosine-Related IncRNA Signature Is a Novel Biomarker of Prognosis and Immune Response in Colon Adenocarcinoma Patients. Front Cell Dev Biol. 2021;9:703629.

38. Huang H, Weng H, Sun W, Qin X, Shi H, Wu H, et al. Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20:285–95.

39. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, et al. A Key Role of DNA Damage-Inducible Transcript 4 (DDIT4) Connects Autophagy and GLUT3-Mediated Steatosis To Desensitize Temozolomide Efficacy in Glioblastomas. Neurotherapeutics. 2020;17:1212–27.

40. Loeweth R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell. 2002;10:457–68.

41. Pópulo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer. Int J Mol Sci. 2012;13:1886–918.

42. Kim J, Kundu M, Vollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13:132–41.

43. Ediriweera MK, Tennekoon KH, Samarakoon SR. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance. Semin Cancer Biol. 2019;59:147–60.

44. Madak-Erdogan Z, Band S, Zhao YC, Smith BP, Kulkuyoulu-Gorulot E, Ezo Q, et al. Free Fatty Acids Rewire Cancer Metabolism in Obesity-Associated Breast Cancer via Estrogen Receptor and mTOR Signaling. Cancer Res. 2019;79:2494–510.

45. Audet-Walsh É, Dufour CR, Yee T, Zouanat FZ, Yan M, Kalloghlian G, et al. Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer. Genes Dev. 2017;31:1228–42.

46. Zhou J, Wang H, Che J, Xu L, Yang W, Li Y, et al. Silencing of microRNA-135b inhibits invasion, migration, and stemness of CD24+(4+CD44(+)) pancreatic cancer stem cells through JADE1-dependent AKT/mTOR pathway. Cancer Cell Int. 2020;20:134.

47. Elsayed AM, Bayraktar E, Amero P, Salama SA, Abdelaziz AH, Ismail RS, et al. PKR/AR1-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway. Int J Mol Sci. 2021;22(4):11882.

48. Zhou M, Guo X, Wang M, Qin R. The patterns of antisense long non-coding RNAs regulating corresponding sense genes in human cancers. J Cancer. 2021;12:1499–506.

49. Huang B, Song JH, Cheng Y, Abraham JM, Ibrahim S, Sun Z, et al. Long non-coding antisense RNA KR77-AS is activated in gastric cancers and supports cancer cell progression by increasing KR77 expression. Oncogene. 2016;35:4927–36.

50. Xu M, Xu X, Pan B, Chen X, Lin K, Zeng K, et al. LncRNA SATB2-AS1 inhibits tumor metastasis and affects the tumor immune cell microenvironment in colorectal cancer by regulating SATB2. Mol Cancer. 2019;18:135.

51. Gupta P, Li YR. Upf proteins: highly conserved factors involved in nonsense mRNA mediated decay. Mol Biol Rep. 2018;45:39–55.

52. Kim YK, Furic L, Desgroseillers L, Maquet LE. Mammalian Staufen1 recruits Upf1 to specific mRNA 3'UTRs so as to elicit mRNA decay. Cell. 2005;120:195–208.

53. Okada-Katsuhata Y, Yamashita A, Kutsuzawa K, Izumi N, Hirahata F, Ohno S. N- and C-terminal Upf1 phosphorylations create binding platforms for SMG-6 and SMG-5 SMG-7 during NMD. Nucleic Acids Res. 2012;40:1251–66.

54. Unterholzer L, Traurialde E. SMG7 acts as a molecular link between endometrial mRNA surveillance and mRNA decay. Mol Cell. 2004;16:587–96.

55. Nicholson P, Yekiposypny H, Metze S, Zamudio Orozco R, Kleinschmidt N, Muhlemann O. Nonsense-mediated mRNA decay in human cells: mechanistic insights, functions beyond quality control and the double-life of NMD factors. Cell Mol Life Sci. 2010;67:677–700.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.